Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04467723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 1, 2024 to Jan 1, 2027v9
  2. Primary completion date changed from estimate of Aug 2024 to Apr 1, 2024 Completion date: Aug 2025 to Aug 2027v8 Show 1 more changeShow less
    • Completion date: Aug 2025 to Aug 2027
  3. Primary completion date: Aug 2023 to Aug 2024 Completion date: Aug 2024 to Aug 2025v7 Show 1 more changeShow less
    • Completion date: Aug 2024 to Aug 2025
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 2022 to May 18, 2022 · Site details revised at 2 of 2 sitesv6 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2022 to May 18, 2022
    • Site details revised at 2 of 2 sites
  5. Primary completion date: Aug 2022 to Aug 2023 Start date: Dec 2021 to Dec 2022 · Completion date: Aug 2023 to Aug 2024v5 Show 2 more changesShow less
    • Start date: Dec 2021 to Dec 2022
    • Completion date: Aug 2023 to Aug 2024
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Start date: Mar 2021 to Dec 2021v3
  3. Primary completion date: Aug 2021 to Aug 2022 Start date: Aug 2020 to Mar 2021 · Completion date: Aug 2022 to Aug 2023v2 Show 2 more changesShow less
    • Start date: Aug 2020 to Mar 2021
    • Completion date: Aug 2022 to Aug 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
Trial Details
NCT Number NCT04467723
Lead Sponsor University of Kansas Medical Center
Collaborators: parkview cancer institute
Conditions NSCLC Stage IV, NSCLC, Recurrent
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov